Company-reported prevalence
Lytenava
Overview
| Field | Value |
|---|---|
| Drug | Lytenava (bevacizumab-vikg) |
| Indication | Neovascular age-related macular degeneration |
| Disease | Wet AMD (wet age-related macular degeneration, neovascular AMD); patients treated with anti-VEGF retinal therapy for the treated-population statement |
| Company | Outlook Therapeutics (developer and marketing authorization holder in the United States, European Union, and United Kingdom); Beijing Syntone Biopharma (joint venture licensee, 80% owned by Syntone Technologies Group; greater China, including Hong Kong, Taiwan, and Macau) |
| Documents searched | Outlook Therapeutics website home, product, and overview pages and the LYTENAVA product website (accessed October 2026); Outlook Therapeutics press releases dated August 2020, March 2021, September 2021, August 2023, November 2024, January 2025, June 2026, July 2026, and August 2026; Form 8-K (September 2026); Form 10-K for fiscal year 2024 (December 2024); Form 10-K for fiscal year 2025 (December 2025); Form 10-Q for the quarter ended June 30, 2026 (August 2026); corporate update presentation (August 2026); no public document from Beijing Syntone Biopharma was identified |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Number affected (adults 40 years or older): Outlook Therapeutics Form 10-K for fiscal year 2025, December 2025
Europe
Number affected: Outlook Therapeutics Form 10-K for fiscal year 2025, December 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number treated (anti-VEGF retinal therapy, all indications): Outlook Therapeutics Form 10-Q for the quarter ended June 30, 2026, August 2026
Global
No evidence found.
Other countries and regions
Number diagnosed: Outlook Therapeutics Form 10-K for fiscal year 2025, December 2025
Cited source: 2.2 GlobalData, undated
(opens the full-size image in a new tab)Incidence: Outlook Therapeutics Form 10-K for fiscal year 2025, December 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Geography not stated
Prevalence (share of all AMD): Outlook Therapeutics Form 10-K for fiscal year 2025, December 2025
Sources the company cites
National eye institute, undated
Passage carrying the figure
Not quoted: The Form 10-K names the National Eye Institute without naming a document or giving an address, and the National Eye Institute page on age-related macular degeneration (accessed October 2026) states neither the 15% share nor the 1.75 million figure.
GlobalData, undated
Reference as the company lists it
Passage carrying the figure
Not quoted: Proprietary market research database sold by GlobalData; the Form 10-K names no report title, date, or address.
GlobalData 2023
Reference as the company lists it
Passage carrying the figure
Not quoted: Proprietary market research sold by GlobalData; the Form 10-Q names no report title or address.
Market scope 2022
Reference as the company lists it
Passage carrying the figure
Not quoted: Proprietary market research report sold by Market Scope, LLC; the Form 10-Q names no report title or address.
IQVIA 2023
Reference as the company lists it
Passage carrying the figure
Not quoted: Proprietary IQVIA MIDAS sales database, available only by license.
Bro 2020
Passage carrying the figure
Not quoted: The abstract reports the proportion of bevacizumab use by country and states no number of treated patients; the full text is not deposited in PMC.